GANX | Gain Therapeutics, Inc.

Index- P/E- EPS (ttm)-1.64 Insider Own24.34% Shs Outstand11.94M Perf Week6.94%
Market Cap59.31M Forward P/E- EPS next Y-1.49 Insider Trans0.00% Shs Float8.99M Perf Month-4.46%
Income-19.50M PEG- EPS next Q-0.28 Inst Own10.20% Short Float / Ratio0.61% / 0.65 Perf Quarter25.13%
Sales0.20M P/S296.54 EPS this Y-8.30% Inst Trans12.98% Short Interest0.06M Perf Half Y62.17%
Book/sh1.27 P/B3.88 EPS next Y0.00% ROA-73.70% Target Price9.00 Perf Year72.98%
Cash/sh1.48 P/C3.33 EPS next 5Y- ROE-93.00% 52W Range2.67 - 6.19 Perf YTD57.51%
Dividend- P/FCF- EPS past 5Y- ROI-91.60% 52W High-20.36% Beta-
Dividend %- Quick Ratio3.70 Sales past 5Y- Gross Margin- 52W Low84.64% ATR0.30
Employees28 Current Ratio3.70 Sales Q/Q47.00% Oper. Margin- RSI (14)51.82 Volatility5.16% 6.39%
OptionableYes Debt/Eq0.04 EPS Q/Q-56.30% Profit Margin- Rel Volume0.56 Prev Close4.81
ShortableYes LT Debt/Eq0.03 EarningsMar 23 AMC Payout- Avg Volume84.89K Price4.93
Recom1.50 SMA20-0.64% SMA500.27% SMA20027.08% Volume47,680 Change2.49%
Date Action Analyst Rating Change Price Target Change
Apr-12-21Initiated Oppenheimer Outperform $30
Apr-12-21Initiated BTIG Research Buy $30
Jun-01-23 08:00AM
May-13-23 08:09AM
May-12-23 09:15AM
May-08-23 10:00AM
09:15AM Loading…
May-03-23 09:15AM
Apr-12-23 04:30PM
Mar-29-23 08:52AM
Mar-23-23 04:05PM
Mar-22-23 08:30AM
Mar-21-23 08:00AM
Mar-09-23 08:00AM
Feb-27-23 08:00AM
Feb-02-23 08:00AM
Jan-17-23 10:00AM
04:05PM Loading…
Jan-12-23 04:05PM
Nov-10-22 05:15PM
Sep-26-22 11:59AM
Sep-20-22 07:30AM
Sep-19-22 08:00AM
Sep-08-22 08:00AM
Sep-06-22 08:00AM
Aug-08-22 09:15AM
Aug-04-22 08:00AM
Aug-03-22 10:00AM
Jun-02-22 08:00AM
May-18-22 08:00AM
05:55PM Loading…
May-16-22 05:55PM
May-11-22 09:30AM
May-06-22 08:00AM
May-03-22 08:31AM
May-02-22 03:00PM
Apr-26-22 05:19PM
Apr-12-22 01:00PM
Mar-29-22 08:00AM
Mar-24-22 08:00AM
Mar-15-22 08:00AM
Mar-01-22 08:00AM
Feb-08-22 08:00AM
Feb-04-22 12:06PM
Jan-31-22 04:05PM
Jan-18-22 08:00AM
Jan-06-22 04:05PM
Dec-28-21 04:05PM
Dec-16-21 06:57AM
Dec-07-21 08:00AM
Dec-01-21 04:07PM
Nov-12-21 09:52AM
Nov-11-21 11:00AM
Nov-10-21 11:00AM
Nov-04-21 04:05PM
Oct-28-21 08:00AM
Oct-26-21 08:00AM
Oct-19-21 08:00AM
Oct-12-21 10:07AM
Sep-23-21 08:00AM
Sep-17-21 08:00AM
Sep-09-21 04:20PM
Sep-08-21 03:51PM
Sep-02-21 04:05PM
Aug-11-21 04:01PM
Aug-03-21 04:05PM
Jun-21-21 05:49PM
Jun-19-21 05:49AM
Jun-10-21 07:30AM
May-27-21 08:00AM
May-17-21 08:00AM
May-10-21 04:01PM
May-03-21 07:30AM
Apr-27-21 04:01PM
Apr-22-21 08:00AM
Apr-20-21 08:00AM
Apr-14-21 09:13PM
Mar-25-21 05:57PM
Mar-18-21 05:08PM
Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. Its lead product candidate includes GT-02287, for the treatment of GBA1 Parkinson's disease. In addition, the company is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.